In people with obesity or overweight, the hazard ratio for new-onset diabetes at 12 months was significantly lower with tirzepatide than with semaglutide (HR = 0.73).
In plain wordsIn people with obesity or overweight, new diabetes was less likely after 12 months on tirzepatide than on semaglutide.
- Peptide
- Tirzepatide
- Outcome
- DecreaseNew-onset type 2 diabetes at 12 months versus semaglutide
- Study
n: not reported in source
- Comparator
- Semaglutide
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- Dose not stated · 12 monthsAs given in this study (human).
Measurements
- Hazard ratio
- 0.73
- tirzepatide versus semaglutide, 12 months
- 95% CI
- 0.58 to 0.92
- tirzepatide versus semaglutide, 12 months
Source sentences
The hazard ratio (HR) for the new-onset diabetes at 12 months following the Tirzepatide intake was significantly lower than that of the Semaglutide group of patients (HR = 0.73, p < 0.001 [95% CI: 0.58-0.92]).
1 context sentence(design, population, supporting numbers)
Database search yielded 2601 studies, among which three studies were eligible (one RCT and two cohort studies) for systematic review.